These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 6352639)

  • 1. Ceftazidime - a significant advance in the treatment of cystic fibrosis.
    David TJ; Phillips BM; Connor PJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():337-40. PubMed ID: 6352639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis.
    Permin H; Koch C; Høiby N; Christensen HO; Møller AF; Møller S
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():313-23. PubMed ID: 6352636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.
    Gold R; Jin E; Levison H; Isles A; Fleming PC
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():331-6. PubMed ID: 6352638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with ceftazidime in cystic fibrosis.
    Dodge J; Zamiri I; Goodchild M; Ingram P
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():325-9. PubMed ID: 6352637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis.
    Strandvik B; Malmborg AS; Alfredson H; Ericsson A
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.
    Heilesen AM; Permin H; Koch C; Høiby N
    Scand J Infect Dis; 1983; 15(3):271-6. PubMed ID: 6417770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftazidime in cystic fibrosis: clinical, microbiological and immunological studies.
    Cullen RT; McCrae WM; Govan J; Raeburn JA; Ingram TM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():369-75. PubMed ID: 6352647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
    Master V; Roberts GW; Coulthard KP; Baghurst PA; Martin A; Roberts ME; Onishko CR; Martin AJ; Linke RJ; Holmes M; Jarvinen A; Kennedy D; Colebatch KA; Hansman D; Parsons DW
    Pediatr Pulmonol; 2001 May; 31(5):367-76. PubMed ID: 11340683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime therapy for serious infections.
    Bint AJ; Constable J; Patton KR; Constable FL
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():115-21. PubMed ID: 6352613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
    Mastella G; Agostini M; Barlocco G; Bonomi U; Borgo G; Bozzino L; Cabrini G; Cappelletti LM; Castellani L; Conforti M
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():297-311. PubMed ID: 6311788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime treatment of chronic Pseudomonas infection in patients with cystic fibrosis.
    Fluge G; Digranes A; Michalsen H; Stiris T; Bergan T; Qvigstad EK
    Eur J Respir Dis; 1987 Oct; 71(4):239-43. PubMed ID: 3319661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxalactam-tobramycin-resistant Pseudomonas aeruginosa isolates in patients with cystic fibrosis.
    Fitzpatrick SB; Rosenstein BJ
    Clin Pediatr (Phila); 1983 Sep; 22(9):628-30. PubMed ID: 6224623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dosage tobramycin treatment of children with cystic fibrosis. Bacteriological effect and clinical ototoxicity.
    Thomsen J; Friis B
    Int J Pediatr Otorhinolaryngol; 1979 Jul; 1(1):33-40. PubMed ID: 553884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response.
    Kercsmar CM; Stern RC; Reed MD; Myers CM; Murdell D; Blumer JL
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():289-95. PubMed ID: 6352634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.
    Byrne S; Maddison J; Connor P; Doughty I; Dodd M; Jenney M; Webb AK; David TJ
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():135-43. PubMed ID: 8543489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis.
    Gold R; Overmeyer A; Knie B; Fleming PC; Levison H
    Pediatr Infect Dis; 1985; 4(2):172-7. PubMed ID: 3885181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
    Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
    J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.